Efficacy of an autogenous vaccine against highly virulent <i>Staphylococcus aureus </i>infection in rabbits
DOI:
https://doi.org/10.4995/wrs.2011.812Keywords:
Staphylococcus aureus, virulence, infection, rabbit, skin, autovaccineAbstract
The efficacy of an autogenous vaccine consisting of a whole cell suspension of formalin killed bacteria in sterile buffered saline against Staphylococcus aureus infections was determined, using a well-established rabbit skin infection model. Thirteen eight-week-old rabbits were vaccinated twice subcutaneously with a two-week interval while ten rabbits were injected twice with sterile buffered saline. Two weeks after the last injection, ten vaccinated and all PBS-injected rabbits were inoculated intradermally with 108 cfu of a S. aureus strain which had been shown to be highly virulent for rabbits. Three vaccinated animals served as negative controls and were intradermally injected with sterile buffered saline. All rabbits were examined daily for the development of skin lesions until fourteen days after the experimental infection when all rabbits were euthanised. All animals experimentally infected with S. aureus developed skin abscesses within 24 hours post-inoculation, but in the vaccinated group the maximum abscess diameter was significantly lower than in the non-vaccinated group (P=0.048). The difference between the autovaccinated and non-vaccinated group increased over time (P<0.001). These results indicate that vaccination with an inactivated whole cell bacterin may be useful for control of staphylococcosis in rabbits but does not prevent abscess formation in animals inoculated with a high dose of a highly virulent S. aureus strain.
Downloads
References
Adlam C., Ward P.D., McCartney A.C., Arbuthnott J.P., Thorley C.M.1977. Effect of immunization with highly purified alpha- and betatoxins on staphylococcal mastitis in rabbits. Infect. Immun., 17: 250-256. https://doi.org/10.1128/IAI.17.2.250-256.1977
Bannoehr J., Ben Zakour N.L., Waller A.S., Guardabassi L., Thoday K.L., van den Broek A.H., Fitzgerald J.R. 2007. Population genetic structure of the Staphylococcus intermedius group: insights into agr diversification and the emergence of methicillin-resistant strains. J. Bacteriol., 189: 8685-8692. doi:10.1128/JB.01150-07. https://doi.org/10.1128/JB.01150-07
Calzolari A., Giraudo J.A., Rampone H., Odierno L., Giraudo A.T.,Frigerio C., Bettera S., Raspanti C., Hernandez J., Wehbe M.,Mattea M., Ferrari M., Larriestra A., Nagel R. 1997. Field trials of a vaccine against bovine mastitis. 2. Evaluation in two commercial dairy herds. J. Dairy Sci., 80: 854-858. doi:10.3168/jds.S0022-0302(97)76007-7. https://doi.org/10.3168/jds.S0022-0302(97)76007-7
Cameron C.M., Fuls W.J.P., Botha W.F. 1979. Composition and evaluation of the efficacy of a Staphylococcus aureus vaccine. Onderstepoort J. Vet., 46: 1-8.
Corpa J.M., Hermans K., Haesebrouck F. 2009. Main pathologies associated with Staphylococcus aureus infections in rabbits: a review. World Rabbit Sci., 17: 115-125. https://doi.org/10.4995/wrs.2009.651
Cotran R.S., Kumar V., Collins T. 1999. Tissue repair: cellular growth,fibrosis, and wound healing. In: Robbins Pathologic Basis of Disease, 6th ed. W.B. Saunders Company, Philadelphia.
Curtis C.F., Lamport A.I., Lloyd D.H. 2006. Masked, controlled study to investigate the efficacy of a Staphylococcus intermedius autogenous bacterin for the control of canine idiopathic recurrent superficial pyoderma. Vet. Dermatol., 17: 163-168. doi: 10.1111/j.1365-3164.2006.00512.x. https://doi.org/10.1111/j.1365-3164.2006.00512.x
Devriese L.A. 1981. Baird-Parker medium supplemented with acriflavine, polymyxins and sulphonamide for the selective isolation of Staphylococcus aureus from heavily contaminated materials. J. Appl. Bacteriol., 50: 351-357. doi: 10.1111/j.13652672.1981.tb00899.x.
Devriese L.A. 1984. A simplified system for biotyping Staphylococcus aureus strains isolated from different animal species. J. Appl. Bacteriol., 56: 215-220. doi : 10.1111/j.1365-2672.1984.tb01341.x. https://doi.org/10.1111/j.1365-2672.1984.tb01341.x
Giraudo J.A., Calzolari A., Rampone H., Rampone A., Giraudo A.T., Bogni C., Larriestra A., Nagel R. 1997. Field trials of a vaccine against bovine mastitis. 1. Evaluation in heifers. J. Dairy Sci., 80: 845-853. doi:10.3168/jds.S0022-0302(97)76006-5. https://doi.org/10.3168/jds.S0022-0302(97)76006-5
Harcourt-Brown F. 2002. Textbook of Rabbit Medicine. Butterworth- Heinemann, London.
Hermans K., De Herdt P., Devriese L.A., Hendrickx W., Godard C.,Haesebrouck F. 1999. Colonisation of rabbits with Staphylococcus aureus in flocks with and without chronic staphylococcosis. Vet. Microbiol., 67: 37-46. doi:10.1016/S0378-1135(99)00028-0. https://doi.org/10.1016/S0378-1135(99)00028-0
Hermans K., De Herdt P., Devriese L.A., Godard C., Haesebrouck F. 2000. Colonisation of rabbits with Staphylococcus aureus after experimental infection with high and low virulence strains. Vet. Microbiol., 72: 277-284. doi:10.1016/S0378-1135(99)00179-0. https://doi.org/10.1016/S0378-1135(99)00179-0
Hermans K., Devriese L.A., Haesebrouck F. 2003. Rabbit staphylococcosis: difficult solutions for serious problems. Vet. Microbiol., 91: 57-64. doi:10.1016/S0378-1135(02)00260-2. https://doi.org/10.1016/S0378-1135(02)00260-2
Hinton M. 1977. Treatment of purulent staphylococcal conjunctivitis in rabbits with autogenous vaccine. Lab. Anim., 11: 163-164. doi: 10.1258/002367777780936756. https://doi.org/10.1258/002367777780936756
Hoedemaker M., Korff B., Edler B., Emmert M., Bleckmann E. 2001.Dynamics of Staphylococcus aureus infections during vaccination with an autogenous bacterin in dairy cattle. J. Vet. Med. B, 48: 373-383. doi: 10.1046/j.1439-0450.2001.00465.x. https://doi.org/10.1046/j.1439-0450.2001.00465.x
Hwang C.Y., Pak S.I., Han H.R. 2000. Effects of autogenous toxoid-bacterin in lactating cows with Staphylococcus aureus subclinical mastitis. J. Vet. Med. Sci.., 62: 875-880. doi: 10.1292/jvms.62.875. https://doi.org/10.1292/jvms.62.875
Kraft W.G., Johnson P.T., David B.C., Morgan D.R. 1986. Cutaneous infection in normal and immunocompromised mice. Infect. Immun.., 52: 707-713. https://doi.org/10.1128/IAI.52.3.707-713.1986
Lee J.C. 1996. The prospects for developing a vaccine against Staphylococcus aureus. Trends Microbiol., 4: 162-166. https://doi.org/10.1016/0966-842X(96)10021-4
Marples R.R., Kligman A.M. 1975. Experimental Staphylococcal infections of the skin in man. In: Jeljaszewicz J. (Ed.), Staphylococci and Staphylococcal Diseases. Proceedings of III International Symposium on Staphylococci and Staphylococcal Infections, Warszawa, Poland, September 8-14, pp.750-755.
Meulemans L., Hermans K., Duchateau L., Haesebrouck F. 2007. High and low virulence Staphylococcus aureus strains in a rabbit skin infection model. Trends Microbiol., 125: 333-340. doi: 10.1016/j.vetmic.2007.05.024. https://doi.org/10.1016/j.vetmic.2007.05.024
Okerman L., Devriese L.A., Maertens L., Okerman F., Godard C. 1984. Cutaneous staphylococcosis in rabbits. Vet. Rec., 114: 313-315. doi: 10.1136/vr.114.13.313. https://doi.org/10.1136/vr.114.13.313
Parker M.T. 1962. Phage typing and the epidemiology of Staphylococcus aureus infection. J. Appl. Bacteriol., 25: 389-402. https://doi.org/10.1111/j.1365-2672.1962.tb04752.x
Projan S.J., Nesin M., Dunman P.M. 2006. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol., 6: 473-479. doi: 10.1016/j.coph.2006.04.005. https://doi.org/10.1016/j.coph.2006.04.005
Vancraeynest D., Hermans K., Deplano A., Denis O., Godard C.,Wildemauwe C., Haesebrouck F. 2006. International dissemination of a high virulence rabbit Staphylococcus aureus clone. J. Vet. Med. B, 53: 418-422. doi: 10.1111/j.1439-0450.2006.00977.x. https://doi.org/10.1111/j.1439-0450.2006.00977.x
Vancraeynest D., Haesebrouck F., Hermans K. 2007. Multiplex PCR for the detection of high virulence Staphylococcus aureus strains from rabbits. Vet. Microbiol., 121: 368-372. doi: 10.1016/j.vetmic.2006.12.011. https://doi.org/10.1016/j.vetmic.2006.12.011
Downloads
Issue
Section
License
This journal is licensed under a "Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)".